Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | ASCO 2016 highlights for multiple myeloma

Rafael Fonseca • 3 Jun 2016
ASCO 2016
Multiple Myeloma Lenalidomide

Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses highlights in multiple myeloma (MM) at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Prof Fonesca mentions presentations looking at the role of stem cell transplant vs conventional therapy, a meta-analysis on the use of maintenance with lenalidomide and a presentation on a dynamic approach to monitoring patients with smouldering myeloma.

More from Rafael Fonseca

0:57
Optimal sequencing of therapies for transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Dec 2023
1:04
The value of MRD in transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Jan 2024
2:10
DRd versus VRd in patients with MM: a real-world retrospective analysis
Rafael Fonseca • 9 Dec 2023
1:52
Secondary cytogenetic abnormalities in MM: prognostic value of chromosome 1q gain vs amplification
Rafael Fonseca • 9 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals